Levitra (Vardenafil, BAY38-9456) + Placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Sexual Dysfunction

Conditions

Sexual Dysfunction, Male Erectile Dysfunction

Trial Timeline

Jul 1, 2006 → Aug 1, 2007

NCT ID

NCT00377793

About Levitra (Vardenafil, BAY38-9456) + Placebo

Levitra (Vardenafil, BAY38-9456) + Placebo is a approved stage product being developed by Bayer for Sexual Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00377793. Target conditions include Sexual Dysfunction, Male Erectile Dysfunction.

What happened to similar drugs?

2 of 8 similar drugs in Sexual Dysfunction were approved

Approved (2) Terminated (0) Active (6)

🔄DapoxetineJohnson & JohnsonPhase 3

✅sildenafilPfizerApproved

✅AlfuzosinSanofiApproved

🔄AVANAFIL + placeboSanofiPhase 3

🔄tibolone + estradiol-norethisteroneOrganonPhase 3

🔄Bremelanotide + PlaceboPalatin TechnologiesPhase 3

🔄BremelanotidePalatin TechnologiesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00666809	Phase 2	Completed	Oct 1, 2006	May 1, 2007	Tinnitus
NCT00377793	Approved	Completed	Jul 1, 2006	Aug 1, 2007	Sexual Dysfunction
NCT00663845	Approved	Completed	May 1, 2006	Apr 1, 2007	Erectile Dysfunction
NCT00657839	Phase 2	Completed	Oct 1, 2005	Jun 1, 2006	Benign Prostatic Hyperplasia
NCT00667979	Approved	Completed	Sep 1, 2004	Dec 1, 2004	Erectile Dysfunction
NCT00663728	Approved	Completed	Sep 1, 2004	Apr 1, 2005	Erectile Dysfunction
NCT00665054	Approved	Completed	Aug 1, 2004	Aug 1, 2005	Erectile Dysfunction
NCT00668096	Approved	Completed	May 1, 2004	Jan 1, 2005	Erectile Dysfunction
NCT00682019	Phase 3	Completed	Dec 1, 2003	Aug 1, 2004	Erectile Dysfunction
NCT00657033	Phase 3	Completed	Oct 1, 2003	Aug 1, 2004	Erectile Dysfunction
NCT00661297	Phase 3	Completed	Jun 1, 2003	Jan 1, 2004	Erectile Dysfunction
NCT00665496	Phase 3	Completed	Jun 1, 2003	Nov 1, 2003	Erectile Dysfunction
NCT00658177	Phase 3	Completed	Jun 1, 2003	Feb 1, 2004	Erectile Dysfunction
NCT00661115	Phase 3	Completed	May 1, 2003	Feb 1, 2004	Erectile Dysfunction
NCT00661596	Phase 3	Completed	May 1, 2003	Jan 1, 2004	Erectile Dysfunction
NCT00661700	Phase 3	Completed	Apr 1, 2003	May 1, 2004	Erectile Dysfunction
NCT00668005	Phase 3	Completed	Feb 1, 2003	Sep 1, 2003	Erectile Dysfunction
NCT00660998	Approved	Completed	Feb 1, 2003	Jan 1, 2004	Erectile Dysfunction
NCT00661219	Phase 3	Completed	Dec 1, 2002	Nov 1, 2003	Erectile Dysfunction
NCT00656188	Phase 2/3	Completed	Oct 1, 2002	May 1, 2003	Erectile Dysfunction

Competing Products

18 competing products in Sexual Dysfunction

See all competitors

Product	Company	Stage	Hype Score
Dapoxetine	Johnson & Johnson	Phase 3	40
Gardasil Vaccine	Merck	Pre-clinical	26
sildenafil	Pfizer	Approved	43
sildenafil	Pfizer	Phase 2	35
CP-866,087 + CP-866,087 + CP-866,087 + Placebo	Pfizer	Phase 2	35
PF-00446687 + Placebo	Pfizer	Phase 2	35
Bremelanotide	Pfizer	Phase 2	35
Sildenafil 100 mg + Placebo	Pfizer	Phase 2	35
Alfuzosin	Sanofi	Approved	43
AVANAFIL + placebo	Sanofi	Phase 3	40
Placebo + 0.5 mgTestosterone + 10 mg Buspirone	Brain Biotech	Phase 2	25
Placebo + Testosterone + Buspirone hydrochloride	Brain Biotech	Phase 2	25
Placebo + Sildenafil + Testosterone	Brain Biotech	Phase 2	25
tibolone + estradiol-norethisterone	Organon	Phase 3	34
Bremelanotide + Placebo	Palatin Technologies	Phase 3	30
bremelanotide	Palatin Technologies	Phase 2	25
Bremelanotide	Palatin Technologies	Phase 3	30
EVO100 + Placebo	Evofem Biosciences	Phase 3	30